Skip to main content

Table 4 Changes of the inflammatory and structural parameters between baseline and week 24

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

Characteristic

Baseline

Week 24

p value

MRI

 PSAMRIS synovitis (median, IQR) (mean ± SD)

1 (0, 2); 2.17 ± 4.61

1 (0, 2); 1.06 ± 1.96

0.008**

 PSAMRIS osteitis (median, IQR) (mean ± SD)

0 (0, 0); 0.44 ± 1.89

0 (0, 0); 0.33 ± 1.41

0.317

 PSAMRIS periarticular (median, IQR) (mean ± SD)

0 (0, 0); 0.28 ± 0.67

0 (0, 0); 0 ± 0

0.102

 PSAMRIS tenossynovitis (median, IQR) (mean ± SD)

0 (0, 1); 0.61 ± 1.15

0 (0, 0); 0.33 ± 0.84

0.096

 PSAMRIS erosions (median, IQR)

2 (0, 4)

2 (0, 4)

1.000

 PSAMRIS proliferation (median, IQR) (mean ± SD)

0 (0, 1); 0.44 ± 0.71

0 (0, 1); 0.44 ± 0.86

1.000

 Total PSAMRIS (median, IQR)

5 (1, 8)

3 (0, 6)

0.005**

HR-pQCT

 Erosion number (median, IQR)

1 (0, 1.75)

1 (0, 1.75)

0.317

 Proliferation grade (median, IQR) (mean ± SD)

0 (0, 1); 0.55 ± 0.76

0 (0, 2); 0.68 ± 0.89

0.180

 Dtot, HA/cm3 (median, IQR)

303.1 (264.8, 320.8)

308.9 (265.8, 324.9)

0.020*

 Dtrab, HA/cm3 (median, IQR)

165.2 (133.5, 205.7)

165.7 (136.9, 206.9)

0.048*

 Dcomp, HA/cm3 (median, IQR)

840.5 (778.8, 848.3)

831.1 (796.5, 854.8)

0.184

 Bone stiffness, kN/mm (median, IQR)

48.38 (38.58, 60.31)

49.40 (38.14, 59.82)

0.501

 Failure load, N (median, IQR)

2312.2 (1862.6, 2817.0)

2390.0 (1798.6, 2847.2)

0.352

  1. Data are based on 18 psoriasis patients with complete baseline and 24-week data
  2. PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system, MRI magnetic resonance imaging, HR-pQCT high-resolution peripheral quantitative computed tomography, IQR interquartile range, Dtot average bone density, HA hydroxyapatite, Dtrab trabecular bone density, Dcomp cortical bone density, N Newton
  3. Additionally reported as mean and standard deviation (mean ± SD) because median was equal to zero
  4. Wilcoxon signed-rank test. *p ≤ 0.05, **p ≤ 0.01